MY104530A - Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. - Google Patents
Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.Info
- Publication number
- MY104530A MY104530A MYPI90002043A MYPI19902043A MY104530A MY 104530 A MY104530 A MY 104530A MY PI90002043 A MYPI90002043 A MY PI90002043A MY PI19902043 A MYPI19902043 A MY PI19902043A MY 104530 A MY104530 A MY 104530A
- Authority
- MY
- Malaysia
- Prior art keywords
- hiv
- recombinant
- particles
- nonreplicating
- immunogens
- Prior art date
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
NONREPLICATING RECOMBINANT- MADE RETROVIRAL PARTICLES HAVING STRUCTURAL, MORPHOLOGICAL AND IMMUNOLOGICAL CHARACTERICTICS VERY SIMILAR TO THOSE OF NATIVE HUMAN RETROVIRUSES ARE DESCRIBED. THE METHOD OF THE INVENTION INVOLVES COEXPRESSION OF MATURE RETROVIRAL CORE AND ENVOLOPE STRUCTURAL PROTEINS IN MAMMALIAN HOST CELLS SUCH THAT THE EXPRESSED RETROOVIRAL PROTEINS ASSOCIATE INTO ASSEMBLED BUDDING RETROVIRAL PARTICLES. IN A PARTICULAR EMBODIMENT OF THE INVENTION NONREPLICATING RECOMBINANT- MADE HIV- 1 PARTICLES ARE PRODUCED BY COINFACTING MAMMALIAN HOST CELLS WITH A RECOMBINANT VACCINIA VIRUS CARRYING THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV- 1) GAG AND PROTEASE GENES AND A RECOMBINANT VACCINIA VIRUS CARRYING THE HIV- 1 ENV GENE. THESE NONREPLICATING RECOMBINANT- MADE HIV- 1PARTICLES HAVE IMMUNOLOGICAL AND MORPHOLOGICAL CHARACTERISTICS CLOSELY RESEMBLING THOSE OF NATIVE HIV- 1, ARE ABLE TO BLOCK THE INFECTIVITY OF LIVE HIV IN VITRO, AND ARE HIGHLY IMMUNOGENIC IN VIVO. THE RECOMBINANT- MADE HIV- 1 PARTICLES OF THE INVENTION MAY BE USED AS ANTI- VIRAL AGENTS AND AS IMMUNOGENS IN VACCINE FORMULATIONS EFFECTIVE AT INHIBITING OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43920589A | 1989-11-20 | 1989-11-20 | |
US61575690A | 1990-11-19 | 1990-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY104530A true MY104530A (en) | 1994-04-30 |
Family
ID=27031958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI90002043A MY104530A (en) | 1989-11-20 | 1990-11-20 | Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. |
Country Status (5)
Country | Link |
---|---|
CN (1) | CN1054613A (en) |
IE (1) | IE904161A1 (en) |
IL (1) | IL96404A0 (en) |
MY (1) | MY104530A (en) |
PT (1) | PT95939A (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7048935B2 (en) | 1995-04-27 | 2006-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US6428790B1 (en) | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US6987096B1 (en) | 1995-04-27 | 2006-01-17 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof |
US6780847B2 (en) | 1995-04-27 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
EP1002091B1 (en) * | 1997-07-09 | 2012-02-29 | Coridon Pty Limited | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
EP1456382B1 (en) | 2001-03-22 | 2007-08-08 | The United States of America, represented by the Secretary, Department of Health and Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
CN104450631A (en) * | 2014-11-11 | 2015-03-25 | 中国人民解放军第四军医大学 | Enterovirus EV71 type VP1 gene virus-like particle as well as preparation method and application thereof |
-
1990
- 1990-11-19 IE IE416190A patent/IE904161A1/en unknown
- 1990-11-19 IL IL9096404A patent/IL96404A0/en unknown
- 1990-11-20 CN CN 90110329 patent/CN1054613A/en active Pending
- 1990-11-20 PT PT9593990A patent/PT95939A/en not_active Application Discontinuation
- 1990-11-20 MY MYPI90002043A patent/MY104530A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1054613A (en) | 1991-09-18 |
IE904161A1 (en) | 1991-05-22 |
IL96404A0 (en) | 1991-08-16 |
PT95939A (en) | 1991-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO921969L (en) | NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS | |
Karacostas et al. | Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. | |
Hahn et al. | Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. | |
Binley et al. | Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins | |
DK33190A (en) | HIV-3 RETROVIRUS AND ITS USE | |
Göttlinger et al. | Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. | |
Morikawa et al. | Identification and analysis of the gag-pol ribosomal frameshift site of feline immunodeficiency virus | |
DK0495811T3 (en) | Production of genetically engineered vaccines against AIDS and other retroviral diseases | |
EP0265785A3 (en) | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells | |
WO1990015066A3 (en) | Nucleotidic sequences resulting from the retrovirus gemone of the hiv-1, hiv-2, and siv type, and their applications, in particular for the amplification of the genomes of said retroviruses and for the in vitro diagnosis of infections caused by these viruses | |
IL89701A0 (en) | Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same | |
WO1991002805A3 (en) | Recombinant retroviruses delivering vector constructs to target cells | |
CA2102918A1 (en) | Genetic vaccine for immunodeficiency viruses | |
ES2140380T3 (en) | DNA SEQUENCES THAT CODE MODIFIED RETROVIRIC POLYPEPTIDES AND VACCINES THAT CONTAIN THEM OR ADDED THEREOF. | |
JP2004509601A5 (en) | ||
MY104530A (en) | Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. | |
YOURNO et al. | Nucleotide sequence analysis of the env gene of a new Zairian isolate of HIV-1 | |
Matthews et al. | Prospects for development of a vaccine against HTLV-III-related disorders | |
SHAROVA et al. | p17 and p17-containing gag precursors of input human immunodeficiency virus are transported into the nuclei of infected cells | |
EP0327180A3 (en) | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 | |
RU2006123079A (en) | VIRUS PARTICLES CONTAINING A VECTOR ORIGINING FROM ALPHAVIRUS AND METHOD FOR PRODUCING THE SPECIFIED VIRUS PARTICLE | |
CA2339850A1 (en) | A non-cytolytic recombinant hiv-1 vaccine | |
RANJBAR et al. | Molecular characterization of an HIV type 1 isolate from Burundi | |
Ferdinand et al. | Perspectives of HIV vaccine developments | |
WO2022035860A3 (en) | Replication-competent adenovirus type 4-hiv env vaccines and their use |